Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds.
On May 7, Raymond James increased its price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) from $123 to $125
The firm also reiterated its Strong Buy rating on the stock, which currently yields a revised upside potential of nearly 40%. Copyright: mikkolem / 123RF Stock Photo The company’s first quarter update showed a lot of progress with its drug pipeline, which included an orphan drug designation for its claseprubart program. The company is also prioritizing DNTH212, which is backed by the dual BDCA2 and BAFF/APRIL procedures.
Raymond James also made note of potential short-term catalysts for the company expected during 2026. These include Phase 1 data along with Phase 2 results for MMN expected during the final quarter. The company also aims to begin the Phase 3 study during mid-year, with a potential topline impact expected sometime in 2028.